|
    HOLX U.S.: Nasdaq

    Hologic Inc.

    Watchlist
    NEW
    Set a price target alert
    HOLXUS
    After Hours
    Last Updated: Nov 10, 2023 6:44 p.m. EST Delayed quote

    $ 71.16

    -0.97 -1.34%
    After Hours Volume: 430.54K
    Close Chg Chg %
    $72.13 4.93 7.34%
    Advanced Charting
    Volume: 4.61M 65 Day Avg: 1.81M
    255% vs Avg
    69.86 Day Range 72.45
    64.02 52 Week Range 87.88

    Partner Center

    Your Watchlists

    Customize MarketWatch

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    No Saved Watchlists

    Create a list of the investments you want to track.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    HOLX Overview

    Key Data

    • Open $69.89
    • Day Range 69.86 - 72.45
    • 52 Week Range 64.02 - 87.88
    • Market Cap $17.67B
    • Shares Outstanding 244.94M
    • Public Float 241.8M
    • Beta 0.84
    • Rev. per Employee $580.42K
    • P/E Ratio 39.37
    • EPS $1.83
    • Yield N/A
    • Dividend N/A
    • Ex-Dividend Date N/A
    • Short Interest 7.14M 10/31/23
    • % of Float Shorted 2.95%
    • Average Volume 1.81M

    Performance

    5 Day
    • 5.04%
    1 Month
    • 4.57%
    3 Month
    • -4.20%
    YTD
    • -3.58%
    1 Year
    • -5.00%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 19 Full Ratings

    Recent News

    Read full story

    Hologic Inc. stock rises Friday, outperforms market

    Read full story

    Hologic Inc. stock outperforms competitors despite losses on the day

    Read full story

    Hologic Inc. stock outperforms competitors despite losses on the day

    Read full story

    Hologic Inc. stock underperforms Tuesday when compared to competitors

    Read full story

    Hologic Inc. stock underperforms Monday when compared to competitors despite daily gains

    Hologic stock falls nearly 4% after company’s revenue drop on lower COVID-related sales

    Hologic upgraded to buy from hold at Needham

    Read full story

    A Skip and Pause Aren’t the Same. What’s Next for Fed’s Inflation Fight.

    Read full story

    Hologic CEO Sees Covid-Era Boom Translating Into Long-Term Growth

    Hologic’s fiscal Q1 tops views, company raises guidance for the year

    Hologic stock jumps, as execs see ‘unprecedented strength’ entering new fiscal year

    Read full story

    Covid Companies Are Losing Steam. Not This One.

    Hologic started at buy with $75 stock price target at Mizuho

    Hologic downgraded to neutral from buy at BofA Securities

    Hologic started at neutral with $73 stock price target at UBS

    Hologic shares rise in falling market after company raises its revenue guidance

    Hologic Inc. shares rose 2.3% Monday in a falling market, after the medical technology company raised its fiscal first-quarter revenue guidance. Marlborough, Mass.-based Hologic said it now expects revenue of about $1.471...

    Read full story

    The S&P 500 looks strong — but these ‘internals’ are far less positive

    Read full story

    This worrisome indicator is a canary in the coal mine for stock-market tops

    Read full story

    5 Undervalued Healthcare Stocks

    Read full story

    Acorns Is the Latest Fintech to Sell to a SPAC

    Assessing Hologic (HOLX)'s Market Valuation: A Closer Look at Its Fair Value

    Assessing Hologic (HOLX)'s Market Valuation: A Closer Look at Its Fair Value

    on GuruFocus.com

    Tech Stocks Soar, Microsoft Reaches Record High As AI Rally Resumes: What's Driving Markets Friday?

    on Benzinga.com

    Big Stocks Moving Higher On Friday: Synaptics Reports Q1 Beat; Joins Lyft, Hologic, Blink Charging

    on Benzinga.com

    Hologic's (HOLX) Q4 Earnings Beat Estimates, Gross Margin Down

    on Zacks.com

    Analysts Conflicted on These Healthcare Names: Vera Therapeutics (VERA) and Hologic (HOLX)

    on TipRanks.com

    Hologic (HOLX) Reports Q4 Earnings: What Key Metrics Have to Say

    on Zacks.com

    Traders Hold Breath For Powell's Remarks, Bitcoin's Wild Ride Unleashed: What's Driving Markets Thursday?

    on Benzinga.com

    Unveiling Hologic (HOLX) Q4 Outlook: Wall Street Estimates for Key Metrics

    on Zacks.com

    Hologic (HOLX) Earnings Expected to Grow: Should You Buy?

    on Zacks.com

    Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know

    on Zacks.com

    Hologic (HOLX) Gains But Lags Market: What You Should Know

    on Zacks.com

    Hologic (HOLX) Q4 Earnings Might Rise on 7.7% Breast Health Growth

    on Zacks.com

    Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?

    on Zacks.com

    Here's Why Hologic (HOLX) Fell More Than Broader Market

    on Zacks.com

    Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It

    on Zacks.com

    Leerink Partners Analyst Assigns Buy Rating to Hologic Based on USPSTF Guidelines and Cervical Cancer Screening Practices

    on TipRanks.com

    Hologic (HOLX) Ascends But Remains Behind Market: Some Facts to Note

    on Zacks.com

    Hologic (HOLX) to Elevate OB-GYN Training With New Partnerships

    on Zacks.com

    Hologic (HOLX) Rises Yet Lags Behind Market: Some Facts Worth Knowing

    on Zacks.com

    Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know

    on Zacks.com

    Hologic Inc.

    Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment focuses on products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment offers the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

    Competitors

    Name Chg % Market Cap
    Johnson & Johnson -0.12% $354.47B
    Abbott Laboratories 0.45% $162.41B
    Medtronic PLC 0.84% $94.04B
    General Electric Co. 1.93% $125.46B
    Siemens Healthineers AG -1.49% €53.45B
    Becton Dickinson & Co. 1.04% $68.07B
    IDEXX Laboratories Inc. 2.38% $35.61B
    Cooper Cos. 1.11% $16.31B
    Qiagen N.V. 0.05% $8.68B
    Palomar Holdings Inc. 3.19% $1.47B